Cardiff Oncology reports Q3 2026 results, preps Phase 3 onvansertib trial for Q1 2027Nov 16Clinical readoutBeiGeneCardiff OncologyUpdated
Pemigatinib bladder cancer trial posts results; study remains active not recruitingNov 16Trial updateIncyte Corporationpemigatinib
FDA granted accelerated approval to retifanlimab-dlwr for Merkel cell carcinoma in 2023Nov 12Regulatory decisionIncyte Corporationretifanlimab
FDA approved axatilimab-csfr for chronic graft-versus-host disease in August 2024Nov 6Regulatory decisionaxatilimab-csfrIncyte Corporation
Incyte posts Phase 3 STOP-HS2 results for povorcitinib; registers INCB161734 Phase 1 studyNov 6Weekly roundup, 2 itemsINCB161734Incyte CorporationUpdated
Incyte reports GVHD cream results; INCA033989 Phase 1 PK study stays activeOct 29Weekly roundup, 2 itemsbioavailability enhancerINCA033989
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
Incyte registers Phase 2 FIGHT-214 trial of pemigatinib in cholangiocarcinomaOct 9Weekly roundup, 2 itemsIncyte CorporationpemigatinibUpdated
Incyte registers two Phase 1 PK studies of INCB161734, in renal and hepatic impairmentOct 2Weekly roundup, 2 itemsINCB161734Incyte CorporationUpdated
FDA approves Incyte's Atebrioz (zilurgisertib) as new molecular entitySep 25Regulatory decisionIncyte Corporation
Incyte registers Phase 2 trial of INCA33890 in MRD-positive colorectal cancerSep 16Trial updateINCA33890Incyte Corporation
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance studySep 11Weekly roundup, 2 itemsadagrasibBristol Myers Squibb
Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancerSep 1Trial updateINCB123667Incyte Corporation
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Incyte posts results for Phase 1/2 anti-PD-1, LAG-3, TIM-3 combo trial in advanced malignanciesAug 17Trial updateINCAGN02385INCAGN02390
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listedAug 14Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega dealJul 28Quarterly updateIncyte Corporation
Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphomaJul 28Trial updateIncyte Corporationrituximab